News – Page 805 – Endpoints News

FDA shoots down Mallinckrodt's redemption attempt, spurns rare kidney disease drug for a second time

5 years ago

Escape Bio nabs $73M as race with well-heeled Biogen and Denali heats up

5 years ago

ICER criticizes cost of 8 targeted immune modulators for UC, recommending some deep discounts

5 years ago

News briefing: Novartis eyes expansion for Eylea rival with PhIII results; Dupixent obtains BTD for EoE

5 years ago

Here's a look at everything Merck's BD group has done in the past 12 years, illustrating why the Seattle Genetics ...

5 years ago

Thanks to a $77.5M Series B, Escient moves into the clinic with the first of its sensory receptor candidates

5 years ago

Trump ups the stakes with 'granddaddy of them all' drug pricing executive order. But he could be running out of time

5 years ago

Arie Belldegrun and David Chang godfather the $110M launch of a new cell therapy player. And this one is also ...

5 years ago

Covid-19 roundup: Eli Lilly declares success on JAK blocker in NIH trial; UK gives small biotech a big vaccine deal

5 years ago

Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an ...

5 years ago

Scoop: Gilead’s CAR-T player Kite waves goodbye to research chief Peter Emtage as another top exec hits the exit

5 years ago

Gilead CEO Dan O'Day's $21B M&A deal to buy Immunomedics gets some harsh reviews

5 years ago

Six days after a startling trial halt, AstraZeneca gets a green light to resume dosing their Oxford Covid-19 vaccine

5 years ago

News briefing: Roche shows off more MS, NMOSD data; Galapagos and Gilead clear PhIIa primary endpoints but report ...

5 years ago

Savara's long-reigning duo both resign in the wake of CF bust

5 years ago

An old Vertex drug gets new life as an Alzheimer's treatment, but human studies still far off

5 years ago

After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone apps

5 years ago

GSK and J&J alum Vijay Reddy to take control of R&D at Tmunity; Andrew Hirsch exits Agios for CEO job at C4 ...

5 years ago

Sarepta CEO Doug Ingram pins gene therapy delay on Covid-burdened FDA, can't offer timeline for fix

5 years ago

A year out from FDA approval, Vertex looks to expand top-selling CF drug to pediatrics

5 years ago

Fasenra shows positive PhIII topline data for nasal polyps, tightening race with GSK's Nucala

5 years ago

Covid-19 roundup: NIH spotlights blood thinners in its next big trial; All it took was a pandemic to get JPM out of ...

5 years ago

Keith Dionne's Casma lines up a $50M venture round to continue the preclinical work on a cellular recycling program

5 years ago

Andrew Hirsch lines up a chunk of equity in his new job as C4 spells out development plans in IPO

5 years ago

First page Previous page 802 803 804805806 807 808 Next page Last page